



ANZGOG 2010 Program



WEDNESDAY 24 February

4.00–6.30pm	<p>Consumer and Community Committee training workshop: Understanding a clinical trial protocol– Sally Baron-Hay</p> <p>Chair: Karen Livingstone Laguna 2</p>	<p>Study Coordinator Workshop: Complementary therapies, the risks and benefits for our patients–Michelle Vaughan</p> <p>Latest trends with targeted therapies– Michael Friedlander</p> <p>Trial Models within ANZGOG– Kim Gillies</p> <p>Research Ethics and Research Governance...parallel or intersecting– Sue Brew</p> <p>Chair: Belinda Egan Noosa Ballroom</p>
6.30–8.30pm	<p>Welcome drinks & canapés</p> <p>Lillypond</p>	

THURSDAY 25 February

7:00–7.50 am Breakfast meeting	<p>Investigator Meeting</p> <p>OUTBACK: A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone.</p> <p>Chair: Linda Mileskin Noosa Ballroom</p>	
8.00–9.00am	<p>INTERNATIONAL GUEST SPEAKER</p> <p>The Role of Chemotherapy in Cervical Cancer– Professor Michael Bookman</p> <p>Chair: Michael Quinn Noosa Ballroom</p>	
9.00–10.00am	<p>ANZGOG and CTC Collaborative Trials Update: Julie Martyn</p> <p>Principal Investigators from all of ANZGOG's current and pending trials, as well as those in the follow up phase, will provide updates as to current trial status.</p> <p>Noosa Ballroom</p>	
10.00–10.30am	<p>Morning tea</p>	

continued over...

<p>10.30–12.30pm</p>	<p>Scientific Session 1 / Free abstracts</p> <p>Chair: Alison Brand Noosa Ballroom</p>  <p><i>Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma</i> –Andreas Obermair</p> <p><i>Early results from the Australian National Endometrial Cancer Study</i> –Penny Webb</p> <p><i>Adjuvant chemotherapy and chemoradiation following surgery for high-risk endometrial cancer</i> –Linda Mileschkin</p> <p><i>The development of a nurse-led psychosocial intervention with peer support for women being treated with radiotherapy for gynaecological cancer(GC)</i> –Penelope Schofield</p> <p><i>LEG'S Study on Lymphoedema</i> –Monika Janda</p> <p><i>Cost of adverse events in gynaecological oncology</i> –Srinivas Kondalsamy-Chennakesavan</p> <p><i>The Ovarian Cancer Patterns of Care Study: Progress and early results</i> –Penelope Webb</p> <p><i>Decision-making in ovarian cancer: Developing and evaluating practical tools to help women make informed treatment choices</i> –Ilona Juraskova</p> <p><i>Prospective study of adequacy of risk-reducing salpingo-oophorectomy in Australasian BRCA1/2 carriers and women at high familial risk of ovarian cancer in the Kathleen Cuninghame Foundation Consortium for Research into Familial Breast Cancer (kConFab)</i> –Belinda Kiely</p>	<p>Consumers & Community Committee Workshop</p> <p>(1) <i>Reviewing a protocol – A consumer's perspective</i>– John Stubbs and Dan Kent</p> <p>(2) <i>Front line experience and consumers FAQs – A Nurse's perspective</i>– Sue Brew and Diana Caruso</p> <p>Laguna 2</p>
<p>12.30–1.30pm</p>	<p>Lunch</p>	<p>Consumer/Clinician luncheon Workshop (by invitation only)</p> <p>Chair: Karen Livingstone Laguna 2</p>
<p>1.30–3.00pm</p>	<p>Scientific Session 2</p> <p><i>PET in gynaecological cancer</i>– Rob Anderson, QLD X-Ray</p> <p><i>Using PET in Clinical Trials:</i>– Bryony Simcock</p> <p><i>CA125 should be used to follow patients with Ovarian Cancer:</i> – Jeff Goh (positive) Vs Orla McNally (negative)</p> <p><i>Follow up of uterine & cervical cancer should rest with the GP</i>– Alison Brand (positive) Vs Bronwyn King (negative)</p> <p>Chair: Andreas Obermair Noosa Ballroom</p>	
<p>3.00–3.15pm</p>	<p>ANZGOG AGM</p> <p>Chair: Michael Quinn Noosa Ballroom</p>	
<p>4.30–5.30pm</p>	<p>Investigator Meeting</p> <p><i>ICON-6: A randomised trial of concurrent cediranib (with platinum-based chemotherapy) and maintenance cediranib in women with platinum-sensitive relapsed ovarian cancer.</i></p> <p>Chair: Michelle Vaughan Noosa Ballroom</p>	
<p>5.30–7.00pm</p>	<p>ANZGOG Nurses Group</p> <p>Co-chair: Judy Eddy & Pauline Tanner Laguna 2</p>	
<p>7 pm</p>	<p>Evening Free</p>	<p>Study Coordinators Committee Meeting</p> <p>Chair: Belinda Egan Laguna 2</p>

7:45–8:45am Breakfast Meeting	<p>Investigator Meeting PARAGON: A Phase 2 study of Anastrozole in women with potentially hormone sensitive recurrent/metastatic gynaecological neoplasms Chair: Michael Friedlander Noosa Ballroom</p>	
9:00–10:00am	<p>Consumers and Community Committee Meeting Chair: Karen Livingstone Laguna 2</p>	
9.00–10.30am	<p>Scientific Session 3 Chair: Anna De Fasio <i>Translational and developmental therapeutic trials (phase I/II) within GOG</i>– Michael Bookman <i>Collection of ascites AOCs</i>– David Bowtell <i>Translational research capabilities of ANECS</i>– Mandy Spurdle Noosa Ballroom</p>	
10.30–11.00am	<p>Morning tea</p>	
11.00–11:45am	<p>Investigator Meeting SYMPTOM BENEFIT II: Does palliative chemotherapy improve symptoms in women with recurrent ovarian cancer? Chair: Michael Friedlander Noosa Ballroom</p>	
11.45–12.45pm	<p>Scientific Session 4 New Trial Concepts Chair: Michael Friedlander Noosa Ballroom</p> <hr/> <p><i>A prospective audit of sentinel node biopsy for Vulval Carcinoma in Australia and New Zealand.</i> Peter Sykes</p> <hr/> <p><i>Conservative management of low risk endometrial Cancer</i> Michael Quinn</p> <hr/> <p><i>The impact of geriatric assessment in older patients receiving 1st line palliative chemotherapy – a randomised trial</i> Christopher Steer</p> <hr/> <p><i>Randomized Phase II Study in Women with Optimally Debulked Advanced Epithelial Ovarian, Fallopian Tube and or Primary Peritoneal Carcinoma (AEOC) Comparing Intravenous and Intra-Peritoneal Cisplatin and Paclitaxel, with Intra-Peritoneal Carboplatin and Paclitaxel with Weekly Intravenous Carboplatin and Paclitaxel.</i> Paul Mainwaring</p>	
12.45– 1.45pm	Lunch	<p>Fundraising Committee Meeting (Working Lunch) Chair: David Bernshaw Noosa Ballroom</p>
1.45–3.45pm	<p>Tumour Board</p>	<p>Scientific Session 5 Chair: Lew Perrin (Noosa Ballroom)</p>
3.45–4.15pm	<p>Afternoon tea</p>	
4.15–5.00pm	<p>Scientific Session 6 Debate: High risk Endometrial Adenocarcinoma chemotherapy– M Bookman (positive) Vs Paul Vasey (negative) Chair: Michael Quinn Noosa Ballroom</p>	
6.30–10.00pm	<p>Prima Biomed Ltd Conference Dinner: (Poolside) Dress: Smart Casual Sheraton Noosa Spa and Resort Poolside</p>	



SATURDAY 27 February

8.30–10.00am	Scientific Session 7 Chair: Michael Friedlander Germ Cell Tumour Panel The Panel: <i>Surgery for Germ Cell Tumours.</i> <i>Is less better?</i> - Jim Nicklin; <i>Dilemmas in GCT</i> –Kathryn Chrystal; <i>Fertility and GCT</i> – Michelle Vaughan Free Abstract: <i>Protection of fertility following anti-cancer therapy by deletion of BC1-2 family killer gene, Puma, in mice</i> - Clare L Scott Noosa Ballroom
10.00–10.30am	Cancer Vaccines in a New Light – Ian Frazer Chair: Michelle Vaughan Noosa Ballroom
10.30–10.45am	Morning tea
10.45–11.45am	RAC Meeting Chair: Michael Friedlander Noosa Ballroom
11.45 – 1:30pm	ANZGOG Board meeting Chair: Michael Quinn Noosa Ballroom

